Last reviewed · How we verify
Colchicines
At a glance
| Generic name | Colchicines |
|---|---|
| Sponsor | French Cardiology Society |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk (PHASE3)
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine (PHASE4)
- Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease (PHASE4)
- Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease (EARLY_PHASE1)
- Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome (NA)
- The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial (PHASE4)
- Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement (NA)
- COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colchicines CI brief — competitive landscape report
- Colchicines updates RSS · CI watch RSS
- French Cardiology Society portfolio CI